AU778829B2 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
AU778829B2
AU778829B2 AU15990/01A AU1599001A AU778829B2 AU 778829 B2 AU778829 B2 AU 778829B2 AU 15990/01 A AU15990/01 A AU 15990/01A AU 1599001 A AU1599001 A AU 1599001A AU 778829 B2 AU778829 B2 AU 778829B2
Authority
AU
Australia
Prior art keywords
ethyl
fluorophenyl
propoxy
pgl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU15990/01A
Other languages
English (en)
Other versions
AU1599001A (en
Inventor
Douglas Wade Beight
Roger Stuart Benjamin
Jerome Herbert Fleisch
William Thomas Mcmillen
Jason Scott Sawyer
Edward C. R. Smith
Beverly Ann Teicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1599001A publication Critical patent/AU1599001A/en
Application granted granted Critical
Publication of AU778829B2 publication Critical patent/AU778829B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU15990/01A 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer Ceased AU778829B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11
US60/164786 1999-11-11
PCT/US2000/031039 WO2001034137A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU1599001A AU1599001A (en) 2001-06-06
AU778829B2 true AU778829B2 (en) 2004-12-23

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15990/01A Ceased AU778829B2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (es)
JP (1) JP2003513916A (es)
KR (1) KR20020069512A (es)
CN (1) CN1390139A (es)
AR (1) AR032432A1 (es)
AU (1) AU778829B2 (es)
BR (1) BR0015490A (es)
CA (1) CA2391416A1 (es)
CZ (1) CZ20021551A3 (es)
EA (1) EA200200545A1 (es)
HK (1) HK1050132A1 (es)
HU (1) HUP0204449A3 (es)
IL (1) IL148579A0 (es)
MX (1) MXPA02004733A (es)
NO (1) NO20022245L (es)
NZ (1) NZ517667A (es)
PE (1) PE20010701A1 (es)
PL (1) PL355172A1 (es)
SK (1) SK6492002A3 (es)
TR (1) TR200201245T2 (es)
WO (1) WO2001034137A2 (es)
ZA (1) ZA200202822B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
CA2408622A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2914587A1 (de) 2012-10-31 2015-09-09 Bayer CropScience AG Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
CN1390139A (zh) 2003-01-08
PL355172A1 (en) 2004-04-05
BR0015490A (pt) 2002-07-09
CZ20021551A3 (cs) 2003-02-12
NO20022245L (no) 2002-07-09
NO20022245D0 (no) 2002-05-10
SK6492002A3 (en) 2003-09-11
ZA200202822B (en) 2003-09-23
HUP0204449A2 (hu) 2003-04-28
PE20010701A1 (es) 2001-07-07
TR200201245T2 (tr) 2004-08-23
AU1599001A (en) 2001-06-06
KR20020069512A (ko) 2002-09-04
AR032432A1 (es) 2003-11-12
WO2001034137A2 (en) 2001-05-17
EP1231938A2 (en) 2002-08-21
WO2001034137A3 (en) 2002-02-14
HUP0204449A3 (en) 2006-02-28
IL148579A0 (en) 2002-09-12
CA2391416A1 (en) 2001-05-17
MXPA02004733A (es) 2002-08-30
JP2003513916A (ja) 2003-04-15
HK1050132A1 (zh) 2003-06-13
NZ517667A (en) 2004-05-28
EA200200545A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
AU778829B2 (en) Oncolytic combinations for the treatment of cancer
TWI331034B (en) Inhibitors of cyclin-dependent kinases and their use
ES2274111T3 (es) Quinolinas como ligandos del receptor de prostaglandinas.
US4511582A (en) Phenanthrene derivatives
CN102791690A (zh) 作为抗癌药的二取代吡啶衍生物
JP2003531194A (ja) プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
JPH0684336B2 (ja) 殺生物性芳香族化合物、その合成および医薬としてのその使用
HU230727B1 (hu) C-aril glükozid SGLT2 inhibitorok szintézis-intermedierei
JPS6089474A (ja) モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
UA73236C2 (en) Pyridasinones having properties of aldosereductase inhibitors
IL41825A (en) Pyridine derivatives their preparation and pharmaceutical compositions containing them
US4551282A (en) Triphenylene derivatives
CA2390789A1 (en) Oncolytic combinations for the treatment of cancer
TW202135831A (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
US20110319458A1 (en) Compound with agitation effect on peroxisome proliferator-activated receptor. process for its preparation and use thereof
ES2207108T3 (es) Derivados de acido aril carboxilico y tetrazol con un grupo de carbamoiloxi.
WO2001034198A2 (en) Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) Oncolytic combinations for the treatment of cancer
JP2007530427A (ja) 細胞毒性作用を有するコンブレタスタチン誘導体
CN116848095B (zh) 氘代化合物
US7531655B2 (en) Large conductance calcium-activated K channel opener
BR112021013348A2 (pt) Composto de fórmula geral, um isômero óptico, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica de combinação e uso do composto
US3726978A (en) Tetrahydropyridazines and pyridazinones as anti-inflammatory agents
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物
US11197873B2 (en) Azolium salts for treatment of non-muscle invasive bladder cancer